tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2012-2-80-89tumors-119Research ArticleОБЗОРЫ И АНАЛИТИКАREVIEWS AND ANALYSISКЛИНИКО-ГЕНЕТИЧЕСКАЯ ГЕТЕРОГЕННОСТЬ МЕЛАНОМЫ КОЖИЛюбченкоЛ. Н.ЧерненкоП. А.ХатыревС. А.ЕмельяноваМ. А.НаседкинаТ. В.ПисареваЕ. Е.КоваленкоС. П.ШаманинВ. А.ФГБУ «РОНЦ им. Н.Н.Блохина» РАМН, МоскваRussian FederationФедеральное государственное бюджетное учреждение науки Институт молекулярной биологии им. В. А. Энгельгардта Российской академии наук, МоскваRussian FederationИнститут молекулярной биологии и биофизики Сибирского Отделения РАМН, НовосибирскRussian FederationООО «БиоЛинк», НовосибирскRussian Federation201221052015228089Copyright © Любченко Л.Н., Черненко П.А., Хатырев С.А., Емельянова М.А., Наседкина Т.В., Писарева Е.Е., Коваленко С.П., Шаманин В.А., 20152015Любченко Л.Н., Черненко П.А., Хатырев С.А., Емельянова М.А., Наседкина Т.В., Писарева Е.Е., Коваленко С.П., Шаманин В.А.Любченко Л.Н., Черненко П.А., Хатырев С.А., Емельянова М.А., Наседкина Т.В., Писарева Е.Е., Коваленко С.П., Шаманин В.А.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/119

Меланома кожи (МК) является этиологически гетерогенным заболеванием, развитие которого связано с воздействием как средовых, так и генетических факторов. С использованием сегрегационного анализа и сравнительной геномной гибридизации были выделены наследственные онкологические синдромы, на фоне которых развивается МК, и картированы гены, вовлеченные в наследственный канцерогенез МК. В молекулярный патогенез спорадической МК вовлечены онкогены и гены-супрессоры, входящие в состав различных сигнальных каскадов. Гиперактивация сигнального пути RAS-RAF-MEK-MAPK наблюдается до 90% случаев МК человека, при этом соматические мутации в гене BRAF являются определяющими в 50-70% случаев МК.

меланома кожинаследственные онкологические синдромысоматические мутации гена BRAFReferencesWoodman SE, Lazar AJ, Aldape KD, et al. New strategies in melanoma: molecular testing in advanced disease. Clin Cancer Res. 2012 Mar 1;18(5):1195-200. Epub 2012 Jan 24.Woodman SE, Lazar AJ, Aldape KD, et al. New strategies in melanoma: molecular testing in advanced disease. Clin Cancer Res. 2012 Mar 1;18(5):1195-200. Epub 2012 Jan 24.Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol. 2009 Jan-Feb;27(1):3-9.]. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. Epub 2009 May 27.Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol. 2009 Jan-Feb;27(1):3-9.]. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. Epub 2009 May 27.Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17;353(20):2135-47.Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17;353(20):2135-47.McCannel TA, Burgess BL, Rao NP, et al. Identification of candidate tumor oncogenes by integrative molecular analysis of choroidal melanoma fine-needle aspiration biopsy specimens. Arch Ophthalmol. 2010 Sep;128(9):1170-7.McCannel TA, Burgess BL, Rao NP, et al. Identification of candidate tumor oncogenes by integrative molecular analysis of choroidal melanoma fine-needle aspiration biopsy specimens. Arch Ophthalmol. 2010 Sep;128(9):1170-7.Haqq C, Nosrati M, Sudilovsky D, et al. The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):6092-7. Epub 2005 Apr 15.Haqq C, Nosrati M, Sudilovsky D, et al. The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):6092-7. Epub 2005 Apr 15.Berking C., Bosserhoff A.K. Malignant Melanoma // Hereditary tumors / Allgayer H., Rehder H., Fulda S. – WILEY-VCH Verlag GmbH & Co.KgaA, 2009 – P. 411-420Berking C., Bosserhoff A.K. Malignant Melanoma // Hereditary tumors / Allgayer H., Rehder H., Fulda S. – WILEY-VCH Verlag GmbH & Co.KgaA, 2009 – P. 411-420Kopf AW, Hellman LJ, Rogers GS, et al. Familial malignant melanoma. JAMA. 1986 Oct 10;256(14):1915-9.Kopf AW, Hellman LJ, Rogers GS, et al. Familial malignant melanoma. JAMA. 1986 Oct 10;256(14):1915-9.Lindor NM, Greene MH. The concise handbook of family cancer syndromes. Mayo Familial Cancer Program. J Natl Cancer Inst. 1998 Jul 15;90(14):1039-71.Lindor NM, Greene MH. The concise handbook of family cancer syndromes. Mayo Familial Cancer Program. J Natl Cancer Inst. 1998 Jul 15;90(14):1039-71.Kefford RF, Newton Bishop JA, Bergman W, et al. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium. J Clin Oncol. 1999 Oct;17(10):3245-51.Kefford RF, Newton Bishop JA, Bergman W, et al. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium. J Clin Oncol. 1999 Oct;17(10):3245-51.Puig S, Malvehy J, Badenas C, et al. Role of the CDKN2A locus in patients with multiple primary melanomas. J Clin Oncol. 2005 May 1;23(13):3043-51.Puig S, Malvehy J, Badenas C, et al. Role of the CDKN2A locus in patients with multiple primary melanomas. J Clin Oncol. 2005 May 1;23(13):3043-51.Somoano B, Niendorf KB, Tsao H. Hereditary cancer syndromes of the skin. Clin Dermatol 2005;23 – P. 85–106Somoano B, Niendorf KB, Tsao H. Hereditary cancer syndromes of the skin. Clin Dermatol 2005;23 – P. 85–106Murphy JA, Barrantes-Reynolds R, Kocherlakota R, et al. The CDKN2A database: Integrating allelic variants with evolution, structure, function, and disease association. Hum Mutat. 2004 Oct;24(4):296-304.Murphy JA, Barrantes-Reynolds R, Kocherlakota R, et al. The CDKN2A database: Integrating allelic variants with evolution, structure, function, and disease association. Hum Mutat. 2004 Oct;24(4):296-304.Hayward N.K. Genetics of melanoma predisposition. Oncogene. 2003 May 19;22(20) – P. 3053-62].Hayward N.K. Genetics of melanoma predisposition. Oncogene. 2003 May 19;22(20) – P. 3053-62].Goldstein A.M., Chan M., Harland M., et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents J Med Genet 2007;44:99–10Goldstein A.M., Chan M., Harland M., et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents J Med Genet 2007;44:99–10Debniak T, van de Wetering T, Scott R, et al. Low prevalence of CDKN2A/ARF mutations among early-onset cancers of breast, pancreas and malignant melanoma in Poland. Eur J Cancer Prev. 2008 Oct;17(5):389-91.Debniak T, van de Wetering T, Scott R, et al. Low prevalence of CDKN2A/ARF mutations among early-onset cancers of breast, pancreas and malignant melanoma in Poland. Eur J Cancer Prev. 2008 Oct;17(5):389-91.Пьянова Д., Озола А., Вейналде Р., и др. Мутации в генах восприимчивости меланомы в Латвии. Тезисы Евразийского форума по меланоме и опухолям кожи. 22-23 июля 2011 г. Стр. 31Пьянова Д., Озола А., Вейналде Р., и др. Мутации в генах восприимчивости меланомы в Латвии. Тезисы Евразийского форума по меланоме и опухолям кожи. 22-23 июля 2011 г. Стр. 31Черненко П.А., Казубская Т.П., Михайловский А.В., и др. Генетические и эпигенетические изменения гена CDKN2A у больных меланомой кожи. Тезисы Евразийского форума по меланоме и опухолям кожи. 22-23 июля 2011 г. Стр. 28Черненко П.А., Казубская Т.П., Михайловский А.В., и др. Генетические и эпигенетические изменения гена CDKN2A у больных меланомой кожи. Тезисы Евразийского форума по меланоме и опухолям кожи. 22-23 июля 2011 г. Стр. 28Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med. 2006 Jul 6;355(1):51-65.Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med. 2006 Jul 6;355(1):51-65.Berger MF, Garraway LA. Applications of genomics in melanoma oncogene discovery. Hematol Oncol Clin North Am. 2009 Jun;23(3):397-414, vii.Berger MF, Garraway LA. Applications of genomics in melanoma oncogene discovery. Hematol Oncol Clin North Am. 2009 Jun;23(3):397-414, vii.Cohen C, Zavala-Pompa A, Sequeira JH, et al. Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin Cancer Res Dec;2002 8(12):3728–33.Cohen C, Zavala-Pompa A, Sequeira JH, et al. Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin Cancer Res Dec;2002 8(12):3728–33.Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature. 2007 Feb 22;445(7130):851-72Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature. 2007 Feb 22;445(7130):851-72Bauer J, Curtin JA, Pinkel D, et al. Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J Invest Dermatol. 2007 Jan;127(1):179-82. Epub 2006 Aug 3.Bauer J, Curtin JA, Pinkel D, et al. Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J Invest Dermatol. 2007 Jan;127(1):179-82. Epub 2006 Aug 3.Houben R, Becker JC, Kappel A, et al. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog. 2004 Mar 26;3(1):6.Houben R, Becker JC, Kappel A, et al. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog. 2004 Mar 26;3(1):6.Stahl JM, Cheung M, Sharma A, et al. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res. 2003 Jun 1;63(11):2881-90.Stahl JM, Cheung M, Sharma A, et al. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res. 2003 Jun 1;63(11):2881-90.Karbowniczek M, Spittle CS, Morrison T, et al. mTOR is activated in the majority of malignant melanomas. J Invest Dermatol. 2008 Apr;128(4):980-7.Epub 2007 Oct 4Karbowniczek M, Spittle CS, Morrison T, et al. mTOR is activated in the majority of malignant melanomas. J Invest Dermatol. 2008 Apr;128(4):980-7.Epub 2007 Oct 4Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006 Sep 10;24(26):4340-6. Epub 2006 Aug 14Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006 Sep 10;24(26):4340-6. Epub 2006 Aug 14Stahl JM, Sharma A, Cheung M, et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 2004 Oct 1;64(19):7002-10Stahl JM, Sharma A, Cheung M, et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 2004 Oct 1;64(19):7002-10Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 2005 Jul 7;436(7047):117-22.Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 2005 Jul 7;436(7047):117-22.Akslen LA, Monstad SE, Larsen B, et al. Frequent mutations of the p53 gene in cutaneous melanoma of the nodular type. Int J Cancer. 1998 Feb 20;79(1):91-5Akslen LA, Monstad SE, Larsen B, et al. Frequent mutations of the p53 gene in cutaneous melanoma of the nodular type. Int J Cancer. 1998 Feb 20;79(1):91-5Kong Y, Kumar SM, Xu X. Molecular pathogenesis of sporadic melanoma and melanoma-initiating cells. Arch Pathol Lab Med. 2010 Dec;134(12):1740-9Kong Y, Kumar SM, Xu X. Molecular pathogenesis of sporadic melanoma and melanoma-initiating cells. Arch Pathol Lab Med. 2010 Dec;134(12):1740-9Eychène A, Barnier JV, Apiou F, et al. Chromosomal assignment of two human B-raf(Rmil) proto-oncogene loci: B-raf-1 encoding the p94Braf/Rmil and B-raf-2, a processed pseudogene. Oncogene. 1992 Aug;7(8):1657-60Eychène A, Barnier JV, Apiou F, et al. Chromosomal assignment of two human B-raf(Rmil) proto-oncogene loci: B-raf-1 encoding the p94Braf/Rmil and B-raf-2, a processed pseudogene. Oncogene. 1992 Aug;7(8):1657-60Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417:949–954.Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417:949–954.Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res Dec 1;2002 62(23):6997–7000.Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res Dec 1;2002 62(23):6997–7000.Gorden A, Osman I, Gai W, et al. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res Jul 15;2003 63(14):3955–7Gorden A, Osman I, Gai W, et al. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res Jul 15;2003 63(14):3955–7James MR, Dumeni T, Stark MS, et al. Rapid screening of 4000 individuals for germ-line variations in the BRAF gene. Clin Chem. 2006 Sep;52(9):1675-8. Epub 2006 Jul 27James MR, Dumeni T, Stark MS, et al. Rapid screening of 4000 individuals for germ-line variations in the BRAF gene. Clin Chem. 2006 Sep;52(9):1675-8. Epub 2006 Jul 27Maldonado JL, Fridlyand J, Patel H, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst Dec 17;2003 95(24):1878–90Maldonado JL, Fridlyand J, Patel H, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst Dec 17;2003 95(24):1878–90Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet Jan;2003 33(1):19–20Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet Jan;2003 33(1):19–20Shinozaki M, Fujimoto A, Morton DL, et al. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res Mar 1;2004 10(5):1753–7Shinozaki M, Fujimoto A, Morton DL, et al. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res Mar 1;2004 10(5):1753–7Davies MA, Samuels Y. Analysis of the genome to personalize therapy for melanoma. Oncogene. 2010 Oct 14;29(41):5545-55. Epub 2010 Aug 9.Davies MA, Samuels Y. Analysis of the genome to personalize therapy for melanoma. Oncogene. 2010 Oct 14;29(41):5545-55. Epub 2010 Aug 9.Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011 Apr 1;29(10):1239-46. Epub 2011 Feb 22.Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011 Apr 1;29(10):1239-46. Epub 2011 Feb 22.Wan PTC, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004; 116:855–867Wan PTC, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004; 116:855–867Heidorn SJ, Milagre C, Whittaker S, et al. Kinasedead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell. 2010 Jan 22;140(2):209-21.Heidorn SJ, Milagre C, Whittaker S, et al. Kinasedead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell. 2010 Jan 22;140(2):209-21.Yancovitz M, Litterman A, Yoon J, et al. Intra- and inter-tumor heterogeneity of BRAF(V600E)) mutations in primary and metastatic melanoma. PLoS One. 2012;7(1):e29336. Epub 2012 Jan 3.Yancovitz M, Litterman A, Yoon J, et al. Intra- and inter-tumor heterogeneity of BRAF(V600E)) mutations in primary and metastatic melanoma. PLoS One. 2012;7(1):e29336. Epub 2012 Jan 3.Liu W, Kelly JW, Trivett M, et al. Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. J Invest Dermatol. 2007 Apr;127(4):900-5Liu W, Kelly JW, Trivett M, et al. Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. J Invest Dermatol. 2007 Apr;127(4):900-5Elder, D.E., Van Belle, P., Elenitsas, R., et al. Neoplastic progression and prognosis in melanoma. Semin. Cutan. Med. Surg., 15: 336–348, 1996.Elder, D.E., Van Belle, P., Elenitsas, R., et al. Neoplastic progression and prognosis in melanoma. Semin. Cutan. Med. Surg., 15: 336–348, 1996.Pacheco I, Buzea C, Tron V. Towards new therapeutic approaches for malignant melanoma. Expert Rev Mol Med. 2011 Nov 1;13:e33.Pacheco I, Buzea C, Tron V. Towards new therapeutic approaches for malignant melanoma. Expert Rev Mol Med. 2011 Nov 1;13:e33.Bauer J, Büttner P, Murali R, et al. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res. 2011 Apr;24(2):345-51Bauer J, Büttner P, Murali R, et al. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res. 2011 Apr;24(2):345-51Ugurel S, Thirumaran RK, Bloethner S, et al. B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS One. 2007 Feb 21;2(2):e236Ugurel S, Thirumaran RK, Bloethner S, et al. B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS One. 2007 Feb 21;2(2):e236Shinozaki M, O’Day SJ, Kitago M, et al. Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin Cancer Res. 2007 Apr 1;13(7):2068-74Shinozaki M, O’Day SJ, Kitago M, et al. Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin Cancer Res. 2007 Apr 1;13(7):2068-74Jovanovic B, Kröckel D, Linden D, et al. Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma. J Invest Dermatol. 2008 Nov;128(11):2696-704. Epub 2008 May 29.Jovanovic B, Kröckel D, Linden D, et al. Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma. J Invest Dermatol. 2008 Nov;128(11):2696-704. Epub 2008 May 29.

The authors declare that there are no conflicts of interest present.